NCT05510895 2025-10-01
NeoBRAF
AIO-Studien-gGmbH
Phase 2 Completed
Clinical Trials
7 trialsNCT03898908 2025-05-21
EBRAIN-MEL
Grupo Español Multidisciplinar de Melanoma
Phase 2 Completed
NCT03843775 2024-10-21
A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT01894672 2024-07-16
BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02631447 2024-06-07
SECOMBIT
Fondazione Melanoma Onlus
Phase 2 Completed
NCT02834364 2023-11-24
GMMG-BIRMA
University of Heidelberg Medical Center
Phase 2 Completed
NCT02902042 2021-02-16
IMMU-TARGET
University Hospital, Essen
Phase 1/2 Completed